Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series Background:Biologic switching is not uncommon in the treatment of psoriasis and is most often due to inadequate response of adverse events. Staying within or switching out of the class is still based on expert opinion but there are published data on intra-class switching with TNF-alpha and IL-17 inhibitors. Less is known about the IL-23 inhibitors because of their limited time in the market. We would like to present our experience with inadequate responders to tildrakizumab, a selective IL23 inhibitor, who were switched to an alternative IL-23 inhibitor.Case Description:This is a case series of 6 patients at a single institution considered inadequate responders to tildrakizumab, which included primary failures, secondary failures, and intermediate responders, who were subsequently switched to another IL-23 inhibitor.Conclusion:All 6 patients who were inadequate responders to tildrakizumab showed significant improvement after switching to another IL-23 inhibitor, with 5/6 reaching IGA 0/1 after 16 weeks of treatment. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Psoriasis and Psoriatic Arthritis SAGE

Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

Download PDF
4 pages

Loading next page...
 
/lp/sage/tildrakizumab-inadequate-responders-switching-to-an-alternative-il-23-1zEQ07LFa9

References (10)

Publisher
SAGE
Copyright
© The Author(s) 2021
ISSN
2475-5303
eISSN
2475-5311
DOI
10.1177/24755303211037308
Publisher site
See Article on Publisher Site

Abstract

Background:Biologic switching is not uncommon in the treatment of psoriasis and is most often due to inadequate response of adverse events. Staying within or switching out of the class is still based on expert opinion but there are published data on intra-class switching with TNF-alpha and IL-17 inhibitors. Less is known about the IL-23 inhibitors because of their limited time in the market. We would like to present our experience with inadequate responders to tildrakizumab, a selective IL23 inhibitor, who were switched to an alternative IL-23 inhibitor.Case Description:This is a case series of 6 patients at a single institution considered inadequate responders to tildrakizumab, which included primary failures, secondary failures, and intermediate responders, who were subsequently switched to another IL-23 inhibitor.Conclusion:All 6 patients who were inadequate responders to tildrakizumab showed significant improvement after switching to another IL-23 inhibitor, with 5/6 reaching IGA 0/1 after 16 weeks of treatment.

Journal

Journal of Psoriasis and Psoriatic Arthritis – SAGE

Published: Oct 1, 2021

Keywords: psoriasis; biologic; treatment; interleukin 23 inhibitor; guselkumab; interleukin 23 inhibitor; tildrakizumab; risankizumab; intraclass switching

There are no references for this article.